Evidence map›Paper›PMID 40736709›Full record

ArticleCancer immunology, immunotherapy : CII2025

VHL restoration in clear cell renal cell carcinoma improves NK cell infiltration and function.

Le Tong, Apple Hui Min Tay, Weiyingqi Cui, Yaxuan Liu, Yanhong Su, Jiawen Lyu, Leila Hoedemakers, Ying Yang, Monika Ehnman, Barbara Seliger and 4 more

Abstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. The emerging role of oncolytic virotherapy in genitourinary malignancies.Frontiers in cell and developmental biology · 2026
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Le Tong *Department of Oncology-Pathology, Karolinska Institutet, J6:20 BioClinicum, Akademiska straket 1, Solna, 17164, Stockholm, Sweden.
Apple Hui Min Tay *Department of Oncology-Pathology, Karolinska Institutet, J6:20 BioClinicum, Akademiska straket 1, Solna, 17164, Stockholm, Sweden.
Weiyingqi CuiDepartment of Oncology-Pathology, Karolinska Institutet, J6:20 BioClinicum, Akademiska straket 1, Solna, 17164, Stockholm, Sweden.
Yaxuan LiuDepartment of Oncology-Pathology, Karolinska Institutet, J6:20 BioClinicum, Akademiska straket 1, Solna, 17164, Stockholm, Sweden.
Yanhong SuDepartment of Oncology-Pathology, Karolinska Institutet, J6:20 BioClinicum, Akademiska straket 1, Solna, 17164, Stockholm, Sweden.
Jiawen LyuDepartment of Oncology-Pathology, Karolinska Institutet, J6:20 BioClinicum, Akademiska straket 1, Solna, 17164, Stockholm, Sweden.
Leila HoedemakersDepartment of Oncology-Pathology, Karolinska Institutet, J6:20 BioClinicum, Akademiska straket 1, Solna, 17164, Stockholm, Sweden.
Ying YangDepartment of Oncology-Pathology, Karolinska Institutet, J6:20 BioClinicum, Akademiska straket 1, Solna, 17164, Stockholm, Sweden.
Monika EhnmanDepartment of Oncology-Pathology, Karolinska Institutet, J6:20 BioClinicum, Akademiska straket 1, Solna, 17164, Stockholm, Sweden.
Barbara SeligerFaculty of Health Sciences Brandenburg, Institute of Translational Immunology, Medical School "Theodor Fontane", Brandenburg an Der Havel, Germany.
Par NordlundDepartment of Oncology-Pathology, Karolinska Institutet, J6:20 BioClinicum, Akademiska straket 1, Solna, 17164, Stockholm, Sweden.
Felix Haglund de FlonDepartment of Oncology-Pathology, Karolinska Institutet, J6:20 BioClinicum, Akademiska straket 1, Solna, 17164, Stockholm, Sweden.
Shi Yong NeoDepartment of Oncology-Pathology, Karolinska Institutet, J6:20 BioClinicum, Akademiska straket 1, Solna, 17164, Stockholm, Sweden.
Andreas LundqvistDepartment of Oncology-Pathology, Karolinska Institutet, J6:20 BioClinicum, Akademiska straket 1, Solna, 17164, Stockholm, Sweden. andreas.lundqvist@ki.se.

Funding

Cancerfonden (#CAN21 1524 Pj and #CAN24 3655 PjDeutsche Forschungsgemeinschaft SE 581/33-1 and SE 581/34-1Karolinska Institutet #2024-03034Radiumhemmets Forskningsfonder #211253 and #241293Robert Lundbergs Minnesstiftelse #2023-01691Robert Lundbergs Minnesstiftelse #2023-01810
6 · The paper itself

Abstract

backgroundThe von Hippel-Lindau (VHL) gene is frequently mutated in clear cell renal cell carcinoma (ccRCC) which results in stabilization of hypoxia-inducible factor (HIF). Despite the well-known immunosuppressive effect of HIF, ccRCC is considered an immunogenic tumor with high lymphocyte infiltration. Since NK cells have a prognostic value in ccRCC patients, it is important to understand how VHL mutations affect NK cell activity and anti-tumor immunity.

methodsTumor spheroids were generated from parental 786-O (VHL-mutated) and 786-O-pVHL (VHL-restored) ccRCC cell lines. Tumor phenotypes, proteome, and secretome were analyzed by flow cytometry, mass spectrometry, and Luminex assays, respectively. Quantitative proteomics analysis and quantitative gene ontology enrichment were used to correlate protein expression changes to ccRCC progression and immunosuppressive pathways. NK cell infiltration, activation, and cytotoxicity were assessed in co-cultures of ccRCC spheroids with NK cells from healthy donors using real-time imaging, immunostaining, and flow cytometry, respectively.

resultsVHL-mutated tumor spheroids were significantly less infiltrated by NK cells compared with VHL-restored tumor spheroids. pVHL-infiltrating NK cells showed an activated phenotype along with the ability to reduce tumor spheroid size. Proteomic analysis revealed that VHL-restored tumors express reduced levels of proteins associated with ccRCC progression and immunosuppression, including components of MHC class I processing and PD-1 signaling. Furthermore, VHL-restored tumors exhibited decreased levels of hypoxia-related and pro-tumoral cytokines, such as GROα, IL-8, IL-10, TRAIL, VEGF, and SCF. Within 768-O tumor spheroids, NK cells displayed a higher degree of hypoxia and expression of HIF1α, and inhibition of HIF1α resulted in higher NK cell infiltration into 786-O spheroids. Similarly, inhibition of the VHL-target gene, HIF2α, in 786-O spheroids resulted in increased NK cell infiltration.

conclusionsVHL mutant tumors are less infiltrated by NK cells due to immunosuppressive pathways driven by HIF stabilization. Restoration of VHL reprograms the tumor microenvironment, reducing ccRCC progression and immunosuppressive signaling while enhancing NK cell infiltration and activation. Inhibition of HIFα improves NK cell infiltration into VHL mutant tumors. Therefore, inhibition of HIFα should be explored as a therapeutic strategy in ccRCC to improve NK cell anti-tumor efficacy against VHL-mutated tumors.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsKiller Cells, NaturalLymphocytes, Tumor-InfiltratingVon Hippel-Lindau Tumor Suppressor ProteinCell Line, TumorHumansMutationProteomicsSpheroids, CellularVHL protein, humanVon Hippel-Lindau Tumor Suppressor ProteinClear cell renal cell carcinomaInfiltrationNK cellsOrganoidSpheroidVHL

Identifiers

PMID40736709
PMCPMC12311085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.